1 / 50

Integrating Hepatitis C and Drug Treatment in a Community-Based Setting

Integrating Hepatitis C and Drug Treatment in a Community-Based Setting. Diana L. Sylvestre, MD O.A.S.I.S. Organization to Achieve Solutions in Substance-Abuse. Who we are:. A nonprofit organization located in Oakland, CA. HIV. TB. STDs. And especially:. Hepatitis C.

nariko
Download Presentation

Integrating Hepatitis C and Drug Treatment in a Community-Based Setting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Integrating Hepatitis C and Drug Treatment in a Community-Based Setting Diana L. Sylvestre, MD O.A.S.I.S. Organization to Achieve Solutions in Substance-Abuse

  2. Who we are:

  3. A nonprofit organization located in Oakland, CA HIV TB STDs And especially: Hepatitis C Mental Illness Dedicated to addressing addiction-related medical conditions including:

  4. “Treatment of patients…who are actively using illicit drugs should be delayed until these habits are discontinued for at least 6 months.” --NIH Consensus Statement on HCV, 1997

  5. The O.A.S.I.S. Group Model

  6. One Stop Shopping

  7. Peer-based education

  8. Support

  9. Contemporaneous medical intervention

  10. Requirements • Honesty • Show up on time • Respect • Peers • Staff

  11. O.A.S.I.S. HCV Patients • >2,000 patients screened to date • Mean age 46 (16-76) • 56% male • Race: • 48% Caucasian • 28% African American • 17% Latino

  12. Drug Use at Engagement • At engagement: • 35% are using heroin • 22% currently using cocaine • 13% currently using methamphetamines • 36% are drinking alcohol • 42% on MMT • 61% report a pre-existing psychiatric condition

  13. Studies • IFN/Ribavirin in methadone patients • PEG-IFN/Riba in methadone patients • Neuropsychiatric monitoring during HCV treatment: building a better Beck • Buprenorphine to transition street-recruited heroin users to HCV treatment • Development of a video-based HCV curriculum for in- and out- of treatment IDUs

  14. HCV Treatment in Methadone Patients • Multicenter study: • Subsites: Gourevitch/Litwin, Bronx, NY A. Williams, Philadelphia, PA • IFN alfa-2b 3mu tiw, ribavirin 1000-1200 qd • Standard monitoring • Group encouraged • Treatment criteria • Interested MMT with active HCV • Reliable attendance

  15. Study Subjects (n=76) • 50 yr • 47 (62%) male • 45 (59%) self-reported psychiatric illness • 23 (30%) had been abstinent < 6mo

  16. Substance Use History • Median lifetime heroin use = 20 yr (3-50) • 27/65 (42%) history of regular cocaine use • Median 3 yr (1-30) • 27/65 (42%) history of regular methamphetamine use • Median 5 yr (1-41) • 41/65 (63%) history of regular MJ use • Median 10 yr (1-46) • 44/69 (64%) history of heavy alcohol use • Median 12 yr (1-43)

  17. Substance Use Behaviors • 15 (20%) drank EtOH during treatment • 27 (36%) used heroin, cocaine, or methamphetamine during treatment • 45 (61%) used any illicit drug during treatment • 33 (45%) increased methadone dose by median of 15 mg (0-180)

  18. Overall Impact of Barriers on Virologic Outcomes p=0.035

  19. Duration of Abstinence vs HCV Treatment Outcomes p=0.18 n=53 n=76 n=23

  20. Drug Use vs HCV Treatment Outcomes p=0.09 n=49 n=8 n=19

  21. Impact of MJ Use on HCV Treatment (p=0.006) n=23 n=74 n=51

  22. The Impact of Preexisting Psychiatric Disease p=0.01 n=31 n=76 n=45

  23. Drug Use vs. Adherence

  24. Factors Contributing to Adherence

  25. Study 2 PEG-IFN/Riba in Methadone-maintained patients

  26. PEG Preliminary Outcomes (n=30)

  27. Caution:Site-based differences in outcomes

  28. Study 3 Bridging Active Heroin Users to HCV Treatment with Buprenorphine

  29. Study Design

  30. RelevanceAll Screened: n=299

  31. Engagement By Race/Ethnicity

  32. Preliminary Treatment Retention (n=92)

  33. Self-reported Drug Use

  34. Self-reported Drug Use

  35. Urine Toxicology

  36. Study 4: Neuropsychiatric Monitoring During HCV Treatment

  37. Pilot Study Design • 40 patient, double-blind • Patients randomized to: • PegIFN alfa-2a plus riba • PegIFN alfa-2b plus riba • Tools: BDI, POMS, HADS, SF-36, MMSE qmo. • Main goal: to look for individual measures that might be predictive of useful outcomes • Secondary goal: to assess whether true differences exist btw the 2 interferons

  38. The Data Looks Fine Sylvestre D, unpublished data

  39. BDI vs Reported Symptoms Psychiatric Symptoms Reported: Depressed Irritable Anxious None Treatment Week

  40. BDI vs Discontinuation Completed Treatment vs Dropouts Treatment Week

  41. Study 5: A Video-based HCV Curriculum for IDUs

  42. Aims • Improve knowledge • Improved attitudes toward change • Improve motivations toward healthy behaviors • Short and long term • In- and out-of-treatment drug users

  43. Current O.A.S.I.S. HCV Curriculum • 4 short peer-based videos • Companion workbook • Positive, educational, upbeat

  44. Study Design • Year 1: Curriculum development • 2 cohorts • In-treatment drug users on methadone maintenance • Out of treatment drug users at syringe exchange • Single session vs multi-session • Standard-of-care comparator • KAM test: before and after

  45. “HCV therapy has been successful even when the patients have not abstained from continued drug or alcohol use... Thus, it is recommended that treatment of active injection drug use be considered on a case-by-case basis, and that active injection drug use in and of itself not be used to exclude such patients from antiviral therapy.” --NIH Consensus Statement on HCV, 2002

  46. Additional Comments • Highly efficient • Not all that hard • Multidisciplinary medical training • ID • Addiction • Psychiatry • BEHAVIOR

  47. Deborah Greene, MD Chris McNeil Many patient volunteers Larry Galindo Tim Maginnis Gerard Wallace Barry Clements, PA-C Alice Asher Laphyne Barrett Beth Klem Lisa Hartfield EBCRP TCHC HEPPAC Acknowledgements

More Related